At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 40 enrolled
Drug / intervention
GSK716155 for injection +1 moredrug
Likely dose
GSK716155 for injection 15 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Assessment of GSK716155 for Type 2 Diabetes Mellitus -A Phase I/II Study to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of GSK716155 in Japanese Subjects With Type 2 Diabetes Mellitus
In Brief
A Phase 1 clinical trial evaluating GSK716155 for injection and Placebo for Diabetes Mellitus, Type 2. Completed, enrolled 40 participants across 3 sites.
Detailed Summary
A Phase I/II study to investigate the safety, pharmacokinetics and pharmacodynamics of GSK716155 in Japanese subjects with type 2 diabetes mellitus
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesJapan
Collaborators--
Timeline
Phase 1CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2007
First PostedSep 2007
Primary CompletionApr 2008
TodayJul 2026
First PostedSep 17, 2007
Enrollment StartAug 1, 2007
Primary CompletionApr 17, 2008
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 18.8 years ago
Interventions
GSK716155 for injectiondrug
GSK716155 will be available with doses of 15 milligrams once a week, 30 milligrams once a week, 50 milligrams biweekly or 100 milligrams once every four weeks.
Placebodrug
Subjects will also receive placebo.